Jenna Dvorin

A new study of AbbVie’s original JAK1-selective inhibitor indicates that it outdoes adalimumab without sacrificing safety in rheumatoid arthritis treatment.

Ixekizumab (Talz) was significantly more likely to both reduce disease activity by ≥50% and achieve complete skin clearance than adalimumab (Humira).